1.
Grant CS: Insulinoma. Best Pract Res Clin Gastroenterol 2005;19:783–798.
2.
de Herder WW: Insulinoma. Neuroendocrinology 2004;80(suppl 1):20-2–20-22.
3.
Rindi G, Kloppel G: Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 2004;80(suppl 1):12-5–12-15.
4.
Service FJ: Insulinoma and other islet-cell tumors. Cancer Treat Res 1997;89:335–346.
5.
Service FJ: Hypoglycemic disorders. N Engl J Med 1995;332:1144–1152.
6.
Service FJ, Natt N, Thompson GB, et al: Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab 1999;84:1582–1589.
7.
Service FJ, Natt N: The prolonged fast. J Clin Endocrinol Metab 2000;85:3973–3974.
8.
Service FJ, Dale AJ, Elveback LR, Jiang NS: Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc 1976;51:417–429.
9.
Anlauf M, Wieben D, Perren A, et al: Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol 2005;29:524–533.
10.
Noone TC, Hosey J, Firat Z, Semelka RC: Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 2005;19:195–211.
11.
Gouya H, Vignaux O, Augui J, et al: CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. Am J Roentgenol 2003;181:987–992.
12.
Semelka RC, Custodio CM, Cem BN, Woosley JT: Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 2000;11:141–148.
13.
Pamuklar E, Semelka RC: MR imaging of the pancreas. Magn Reson Imaging Clin N Am 2005;13:313–330.
14.
Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB: Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000;214:483–490.
15.
Owen NJ, Sohaib SA, Peppercorn PD, et al: MRI of pancreatic neuroendocrine tumours. Br J Radiol 2001;74:968–973.
16.
Catalano C, Pavone P, Laghi A, et al: Localization of pancreatic insulinomas with MR imaging at 0.5 T. Acta Radiol 1999;40:644–648.
17.
Kann PH, Rothmund M, Zielke A: Endoscopic ultrasound imaging of insulinomas: limitations and clinical relevance. Exp Clin Endocrinol Diabetes 2005;113:471–474.
18.
McLean AM, Fairclough PD: Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab 2005;19:177–193.
19.
Jackson JE: Angiography and arterial stimulation venous sampling in the localization of pancreatic neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2005;19:229–239.
20.
Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA: Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025–1026. Arch Surg 2001;136:1020–1025.
21.
Norton JA: Intraoperative methods to stage and localize pancreatic and duodenal tumors. Ann Oncol 1999;10(suppl 4):182–184.
22.
Grover AC, Skarulis M, Alexander HR, et al: A prospective evaluation of laparoscopic exploration with intraoperative ultrasound as a technique for localizing sporadic insulinomas. Surgery 2005;138:1003–1008.
23.
Berends FJ, Cuesta MA, Kazemier G, et al: Laparoscopic detection and resection of insulinomas. Surgery 2000;128:386–391.
24.
Vezzosi D, Bennet A, Rochaix P, et al: Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 2005;152:757–767.
25.
Krenning EP, Kwekkeboom DJ, Bakker WH, et al: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716–731.
26.
Bertherat J, Tenenbaum F, Perlemoine K, et al: Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003;88:5353–5360.
27.
Orlefors H, Sundin A, Garske U, et al: Whole-body 11C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392–3400.
28.
Eriksson B, Orlefors H, Oberg K, Sundin A, Bergstrom M, Langstrom B: Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005;19:311–324.
29.
Aranha GV, Shoup M: Nonstandard pancreatic resections for unusual lesions. Am J Surg 2005;189:223–228.
30.
Kaczirek K, Asari R, Scheuba C, Niederle B: Organic hyperinsulinism and endoscopic surgery. Wien Klin Wochenschr 2005;117:19–25.
31.
Stabile BE: Islet cell tumors. Gastroenterologist 1997;5:213–232.
32.
Stehouwer CD, Lems WF, Fischer HR, Hackeng WH: Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug? Neth J Med 1989;35:86–94.
33.
Cohen MS, Bower RH, Fidler SM, Johnsonbaugh RE, Sode J: Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma. Lancet 1973;i:40–41.
34.
Brodows RG, Campbell RG: Control of refractory fasting hypoglycemia in a patient with suspected insulinoma with diphenylhydantoin. J Clin Endocrinol Metab 1974;38:159–162.
35.
Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ: Octreotide. N Engl J Med 1996;334:246–254.
36.
Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA: Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (sandostatin). Acta Endocrinol (Copenh) 1989;121:34–40.
37.
Eriksson B, Oberg K, Alm G, et al: Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet 1986;ii:1307–1309.
38.
Danforth DN Jr, Gorden P, Brennan MF: Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 1984;96:1027–1037.
39.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–2762.
40.
O’Toole D, Maire F, Ruszniewski P: Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 2003;10:463–468.
41.
Rougier P, Mitry E: Chemotherapy in the treatment of neuroendocrine malignant tumors. Digestion 2000;62(suppl 1):73-8–73-78.
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.